Sera proteomic biomarker profiling in HIV-1 infected subjects with cognitive impairment

Wojciech Rozek, Jayme Horning, James Anderson, Pawel S Ciborowski

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

HIV-1 infection of the brain commonly leads to cognitive impairments (CIs). In its most severe form, HIV-1 associated dementia (HAD) is associated with advanced immune suppression and debilitating loss of memory, behavioral, and motor functions. Despite significant research activities, diagnosis remains one of exclusion. Bioimaging, neuropsychological testing, and viral and immune biomarkers serve to support but not define a diagnosis of HIV-1 associated CI. This is timely and required as brain injury triggered by HIV-1 can be controlled, in part, by antiretroviral medicines. The recent development of proteomics has opened new ways to study viral-host interactions which may provide new insight into treatment and disease monitoring. To this end, we developed a proteomics platform for HIV-1 associated CI biomarker discovery and used it to perform a pilot study for sera-associated HAD proteins. A 2-DE map of a serum proteome was focused on differentially expressed proteins. Differential expression of two proteins was validated by Western blot tests identifying afamin and ceruloplasmin as a potential biomarkers for CI associated with advanced HIV-1 infection.

Original languageEnglish (US)
Pages (from-to)1498-1507
Number of pages10
JournalProteomics - Clinical Applications
Volume2
Issue number10-11
DOIs
StatePublished - Dec 1 2008

Fingerprint

Biomarkers
Proteomics
HIV-1
Brain
Serum
Proteins
Ceruloplasmin
Proteome
Medicine
HIV Infections
Dementia
Data storage equipment
Monitoring
Testing
Memory Disorders
Cognitive Dysfunction
Brain Injuries
Western Blotting
Research

Keywords

  • 2-D DIGE
  • Biomarker
  • Cognitive impairment
  • HIV-1

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Sera proteomic biomarker profiling in HIV-1 infected subjects with cognitive impairment. / Rozek, Wojciech; Horning, Jayme; Anderson, James; Ciborowski, Pawel S.

In: Proteomics - Clinical Applications, Vol. 2, No. 10-11, 01.12.2008, p. 1498-1507.

Research output: Contribution to journalArticle

Rozek, Wojciech ; Horning, Jayme ; Anderson, James ; Ciborowski, Pawel S. / Sera proteomic biomarker profiling in HIV-1 infected subjects with cognitive impairment. In: Proteomics - Clinical Applications. 2008 ; Vol. 2, No. 10-11. pp. 1498-1507.
@article{07953fd287084569a8b70e8d587e6308,
title = "Sera proteomic biomarker profiling in HIV-1 infected subjects with cognitive impairment",
abstract = "HIV-1 infection of the brain commonly leads to cognitive impairments (CIs). In its most severe form, HIV-1 associated dementia (HAD) is associated with advanced immune suppression and debilitating loss of memory, behavioral, and motor functions. Despite significant research activities, diagnosis remains one of exclusion. Bioimaging, neuropsychological testing, and viral and immune biomarkers serve to support but not define a diagnosis of HIV-1 associated CI. This is timely and required as brain injury triggered by HIV-1 can be controlled, in part, by antiretroviral medicines. The recent development of proteomics has opened new ways to study viral-host interactions which may provide new insight into treatment and disease monitoring. To this end, we developed a proteomics platform for HIV-1 associated CI biomarker discovery and used it to perform a pilot study for sera-associated HAD proteins. A 2-DE map of a serum proteome was focused on differentially expressed proteins. Differential expression of two proteins was validated by Western blot tests identifying afamin and ceruloplasmin as a potential biomarkers for CI associated with advanced HIV-1 infection.",
keywords = "2-D DIGE, Biomarker, Cognitive impairment, HIV-1",
author = "Wojciech Rozek and Jayme Horning and James Anderson and Ciborowski, {Pawel S}",
year = "2008",
month = "12",
day = "1",
doi = "10.1002/prca.200780114",
language = "English (US)",
volume = "2",
pages = "1498--1507",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",
number = "10-11",

}

TY - JOUR

T1 - Sera proteomic biomarker profiling in HIV-1 infected subjects with cognitive impairment

AU - Rozek, Wojciech

AU - Horning, Jayme

AU - Anderson, James

AU - Ciborowski, Pawel S

PY - 2008/12/1

Y1 - 2008/12/1

N2 - HIV-1 infection of the brain commonly leads to cognitive impairments (CIs). In its most severe form, HIV-1 associated dementia (HAD) is associated with advanced immune suppression and debilitating loss of memory, behavioral, and motor functions. Despite significant research activities, diagnosis remains one of exclusion. Bioimaging, neuropsychological testing, and viral and immune biomarkers serve to support but not define a diagnosis of HIV-1 associated CI. This is timely and required as brain injury triggered by HIV-1 can be controlled, in part, by antiretroviral medicines. The recent development of proteomics has opened new ways to study viral-host interactions which may provide new insight into treatment and disease monitoring. To this end, we developed a proteomics platform for HIV-1 associated CI biomarker discovery and used it to perform a pilot study for sera-associated HAD proteins. A 2-DE map of a serum proteome was focused on differentially expressed proteins. Differential expression of two proteins was validated by Western blot tests identifying afamin and ceruloplasmin as a potential biomarkers for CI associated with advanced HIV-1 infection.

AB - HIV-1 infection of the brain commonly leads to cognitive impairments (CIs). In its most severe form, HIV-1 associated dementia (HAD) is associated with advanced immune suppression and debilitating loss of memory, behavioral, and motor functions. Despite significant research activities, diagnosis remains one of exclusion. Bioimaging, neuropsychological testing, and viral and immune biomarkers serve to support but not define a diagnosis of HIV-1 associated CI. This is timely and required as brain injury triggered by HIV-1 can be controlled, in part, by antiretroviral medicines. The recent development of proteomics has opened new ways to study viral-host interactions which may provide new insight into treatment and disease monitoring. To this end, we developed a proteomics platform for HIV-1 associated CI biomarker discovery and used it to perform a pilot study for sera-associated HAD proteins. A 2-DE map of a serum proteome was focused on differentially expressed proteins. Differential expression of two proteins was validated by Western blot tests identifying afamin and ceruloplasmin as a potential biomarkers for CI associated with advanced HIV-1 infection.

KW - 2-D DIGE

KW - Biomarker

KW - Cognitive impairment

KW - HIV-1

UR - http://www.scopus.com/inward/record.url?scp=64749112915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64749112915&partnerID=8YFLogxK

U2 - 10.1002/prca.200780114

DO - 10.1002/prca.200780114

M3 - Article

C2 - 21136797

AN - SCOPUS:64749112915

VL - 2

SP - 1498

EP - 1507

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

IS - 10-11

ER -